« Back
Home /
Darifenacin (hydrobromide)

Darifenacin (hydrobromide)

Item no.	HY-A0012-5mg
Manufacturer	MedChem Express
CASRN	133099-07-7
Amount	5 mg
Quantity options	100 mg 10 mM/1 mL 10 mg 50 mg 5 mg
Category	Inhibitors & Compound Libraries Small Molecules
Type	Inhibitors
Specific against	other
Purity	99.97
Citations	[1]Hegde SS, et al. Functional role of M2 and M3 muscarinic receptors in the urinary bladder of rats in vitro and in vivo. Br J Pharmacol, 1997, 120(8), 1409-1418.\|[2]Iijima K, et al. Effects of the M3 receptor selective muscarinic antagonist darifenacin on bladder afferent activity of the rat pelvic nerve. Eur Urol, 2007, 52(3), 842-847.\|[3]Seo MS, et al. Suppression of voltage-gated K<sup>+</sup> channels by darifenacin in coronary arterial smooth muscle cells. Eur J Pharmacol. 2021 Jan 15;891:173707.\|[4]Hering NA, et al. Blockage of Cholinergic Signaling via Muscarinic Acetylcholine Receptor 3 Inhibits Tumor Growth in Human Colorectal Adenocarcinoma. Cancers (Basel). 2021 Jun 28;13(13):3220.\|[5]Khurana S, et al. Effects of modulating M3 muscarinic receptor activity on azoxymethane-induced liver injury in mice. Biochem Pharmacol. 2013 Jul 15;86(2):329-38. \|[6]Yamada S, et al. In vivo demonstration of M3 muscarinic receptor subtype selectivity of darifenacin in mice. Life Sci. 2006 Dec 14;80(2):127-32. ACS Omega. 2020 Oct 12;5(41):26551-26561.\|Eur J Pharmacol. 2011 Aug 1;663(1-3):74-9. \|J Transl Med. 2025 Jan 23;23(1):112.\|Br J Pharmacol. 2015 Dec;172(23):5619-33. \|Oncotarget. 2016 Apr 5;7(14):18085-94. \|Sci Rep. 2017 Jan 19;7:40802.
Smiles	O=C(C(C1=CC=CC=C1)([C@@H]2CCN(CCC3=CC4=C(OCC4)C=C3)C2)C5=CC=CC=C5)N.Br
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	UK-88525 (hydrobromide)
Shipping Condition	Room temperature
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	Cancer-programmed cell death
Manufacturer - Targets	Akt; mAChR; p38 MAPK
Shipping Temperature	Room Temperature
Storage Conditions	4°C (Powder, sealed storage, away from moisture)
Molecular Weight	507.46
Product Description	Darifenacin (UK-88525) hydrobromide is a selective and orally active M3 muscarinic receptor (M3R) antagonist with a pKi of 8.9. Darifenacin hydrobromide binds >20-fold more specifically to M3R than to other muscarinic receptors. Darifenacin hydrobromide can be used in the study of urinary incontinence and other symptoms of overactive bladder. Darifenacin hydrobromide inhibits tumor growth in colorectal cancer cells and has anti-tumor effects[1][2][3][4][5][6].
Manufacturer - Research Area	Cancer; Metabolic Disease; Neurological Disease
Solubility	DMSO: 33.33 mg/mL (ultrasonic)
Manufacturer - Pathway	GPCR/G Protein; MAPK/ERK Pathway; Neuronal Signaling; PI3K/Akt/mTOR
Isoform	ERK1; ERK2; mAChR3; MMP-1
Clinical information	Launched

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-A0012-5mg-safety-datasheet.pdf